stated value of capital stock, paid-in capital in excess of par, retained earnings or other capital accounts. The term equity capital does not include securities in the securities accounts of partners and balances in limited partners' capital accounts in excess of their stated capital contributions.

(iii) Paragraphs (i)(1) and (i)(2) of this section shall not preclude a government securities broker or dealer from making required tax payments or preclude the payment to partners of reasonable compensation, and such payments shall not be included in the calculation of withdrawals, advances or loans for purposes of paragraphs (i)(1) and (i)(2) of this section.

(iv) For the purposes of this subsection (i), any transaction between a government securities broker or dealer and a stockholder, partner, sole proprietor, employee or affiliate that results in a diminution of the government securities broker's or dealer's liquid capital shall be deemed to be an advance or loan of liquid capital.

* * * * *

(Approved by the Office of Management and Budget under control number 1535–0089)

4. By adding § 402.2e (Appendix E) as follows:

§ 402.2e Appendix E—Temporary Minimum Requirements.

(a) A government securities broker or dealer that falls within the provisions of paragraph (b)(1) of § 402.2 shall maintain not less than the greater of:

(1) The amount of liquid capital required under paragraph (a) of § 402.2(a); or

(2) The amount of liquid capital, after deducting total haircuts, of:

(i) $25,000 through June 30, 1995;

(ii) $100,000 from July 1, 1995 through December 31, 1995;

(iii) $175,000 from January 1, 1996 through June 30, 1996; and

(iv) $250,000 from July 1, 1996 and thereafter.

(b) A government securities broker or dealer that falls within the provisions of paragraph (b)(2) of § 402.2 shall maintain not less than the greater of:

(1) The amount of liquid capital required under paragraph (a) of § 402.2; or

(2) The amount of liquid capital, after deducting total haircuts, of:

(i) $25,000 through June 30, 1995;

(ii) $50,000 from July 1, 1995 through December 31, 1995;

(iii) $75,000 from January 1, 1996 through June 30, 1996; and

(iv) $100,000 from July 1, 1996 and thereafter.

(c) A government securities broker that falls within the provisions of paragraph (c)(1) of § 402.2 shall maintain not less than the greater of:

(1) The amount of liquid capital required under paragraph (a) of § 402.2; or

(2) The amount of liquid capital, after deducting total haircuts, of:

(i) $5,000 through June 30, 1995;

(ii) $20,000 from July 1, 1995 through December 31, 1995;

(iii) $35,000 from January 1, 1996 through June 30, 1996; and

(iv) $50,000 from July 1, 1996 and thereafter.

(d) A government securities broker that falls within the provisions of paragraph (c)(2) of § 402.2 shall maintain not less than the greater of:

(1) The amount of liquid capital required under paragraph (a) of § 402.2; or

(2) The amount of liquid capital, after deducting total haircuts, of:

(i) $5,000 through June 30, 1995;

(ii) $11,000 from July 1, 1995 through December 31, 1995;

(iii) $18,000 from January 1, 1996 through June 30, 1996; and

(iv) $25,000 from July 1, 1996 and thereafter.

* * * * *

PART 404—RECORDKEEPING AND PRESERVATION OF RECORDS

5. The authority citation for Part 404 is revised to read as follows:

Authority: 15 U.S.C. 78o–5(b)(1)(B), (b)(1)(C), (b)(4).

6. Section 404.2 is amended by revising paragraph (a)(4) to read as follows:

§ 404.2 Records to be made and kept current by registered government securities brokers and dealers; records of non-resident registered government securities brokers and dealers.

(a) * * *

(4) Paragraph 240.17a–3(b)(1) is modified to read as follows:

''(1) This section shall not be deemed to require a government securities broker or dealer registered pursuant to Section 15C(a)(1)(A) of the Act (15 U.S.C. 78o–5(a)(1)(A)) to make or keep such records of transactions cleared for such government securities broker or dealer as are customarily made and kept by a clearing broker or dealer pursuant to the requirements of §§ 240.17a–3 and 240.17a–4: *Provided*, that the clearing broker or dealer has and maintains net capital of not less than $250,000 (or, in the case of a clearing broker or dealer that is a registered government securities broker or dealer, liquid capital less total haircuts, determined as provided in § 402.2 of this title, of not less than $250,000) and is otherwise in compliance with § 240.15c3–1, § 402.2 of this title, or the capital rules of the exchange of which such clearing broker or dealer is a member if the members of such exchange are exempt from § 240.15c3–1 by paragraph (b)(2) thereof.''.

* * * * *

§§ 400.4, 400.5, 401.9, 403.5, 404.2, 404.3, 404.4, 404.5, 405.2, and 450.4 [Amended]

7. For each section indicated in the list above, remove the Office of Management and Budget control number from the parenthetical statement at the end of each section, and add in its place ''1535–0089'':

Dated: February 15, 1995.

Frank N. Newman,

Deputy Secretary.

[FR Doc. 95–4941 Filed 2–28–95; 8:45 am]

BILLING CODE 4810–39–W

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 450

[Docket No. 94N–0302]

Antibiotic Drugs; Bleomycin Sulfate; Stay of Regulation

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; stay of regulation.

SUMMARY: The Food and Drug Administration (FDA) is staying a regulation that established standards for an antibiotic drug, bleomycin sulfate bulk drug substance. This action is being taken in response to a petition for stay of action.

EFFECTIVE DATE: November 9, 1994.

FOR FURTHER INFORMATION CONTACT: Tamar S. Nordenberg, Center for Drug Evaluation and Research (HFD–366), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–2041.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of October 4, 1994 (59 FR 50484), FDA published, as a final rule to become effective on November 3, 1994, a new antibiotic regulation setting forth standards for a bleomycin sulfate bulk drug substance (21 CFR 450.10). This new regulation differed from the monograph standards for sterile bleomycin sulfate bulk drug, set forth in 21 CFR 450.10a, in two respects: The new regulation did not require sterility at the bulk stage, and the new regulation

did not require testing for pyrogens at the bulk stage.

Bristol-Myers Squibb Co., the manufacturer of the innovator product, filed a petition for stay of action pursuant to 21 CFR 10.35, objecting to FDA's decision to promulgate the new regulation without notice and a prior opportunity for public comment. On November 9, 1994, FDA agreed to stay the effective date of the monograph for bleomycin sulfate bulk drug substance in order to reconsider the manner in which the agency promulgated the new monograph. A copy of FDA's letter notifying Bristol-Myers Squibb Co. of the stay is on file in the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 450 is amended as follows:

List of Subjects in 21 CFR Part 450

Antibiotics.

PART 450—ANTITUMOR ANTIBIOTIC DRUGS

1. The authority citation for 21 CFR part 450 continues to read as follows:

Authority: Sec. 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357).

§ 450.10 [Stayed]

2. Section 450.10 *Bleomycin sulfate* is stayed effective November 9, 1994.

Dated: February 15, 1995.

Murray M. Lumpkin,

Deputy Director, Center for Drug Evaluation and Research.

[FR Doc. 95–5058 Filed 2–28–95; 8:45 am]

BILLING CODE 4160–01–F

21 CFR Parts 510 and 558

Animal Drugs, Feeds, and Related Products; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for nine new animal drug applications (NADA's) from Agri-Bio Corp. to Hoffman-LaRoche, Inc. This document also corrects an inadvertent error in the animal drug regulations.

EFFECTIVE DATE: March 1, 1995.

FOR FURTHER INFORMATION CONTACT: Benjamin A. Puyot, Center for Veterinary Medicine (HFV–130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1646.

SUPPLEMENTARY INFORMATION: Agri-Bio Corp., 966 Dorsey St., Gainesville, GA 30501, has informed FDA that it has transferred the ownership of, and all rights and interests in, the following approved NADA's to Hoffmann-La Roche, Inc., 340 Kingsland St., Nutley, NJ 07110–1199:

NADA No.	Ingredient(s)	Trade name(s)
128–686 ...	Salinomycin	Bio-Cox.
132–447 ...	Salinomycin and Roxarsone	Bio-Cox and 3-Nitro.
134–284 ...	Salinomycin and Bambermycins	Bio-Cox and Flavomycins.
134–185 ...	Salinomycin and Roxarsone and Bambermycins	Bio-Cox and 3-Nitro Flavomycin.
135–321 ...	Salinomycin and Roxarsone and Bacitracin-MD	Bio-Cox and 3-Nitro and BMD.
135–746 ...	Salinomycin and Bacitracin-MD	Bio-Cox and BMD.
137–536 ...	Salinomycin and Roxarsone and Bacitracin Zn	Bio-Cox and 3-Nitro and Albac.
137–537 ...	Salinomycin and Lincomycin	Bio-Cox and Lincomix.
140–581 ...	Salinomycin and Roxarsone and Lincomycin	Bio-Cox and 3–Nitro and Lincomix.

Accordingly, the agency is amending the regulations in 21 CFR 510.600(c)(1) and (c)(2) and 558.95(b)(1)(xi)(*b*) and (b)(1)(xii)(*b*) to reflect the change of sponsor.

In the **Federal Register** of January 13, 1995 (60 FR 3079 at 3080), FDA amended § 558.550; this amendment inadvertently failed to reflect a previous amendment published in the **Federal Register** of December 29,1994 (59 FR 67185). The December 29, 1994, document amended § 558.550(a)(1) and (a)(2) to provide for specific levels of Type A articles approved for use for the specified sponsors. The January 13, 1995, document amended § 558.550(a)(2) to add approved referenced uses as stated in § 558.550(b). This document corrects the inadventent error made in the final rule of January 13, 1995.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 558 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: Secs. 201, 301, 501, 502, 503, 512, 701, 721 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e).

§ 510.600 [Amended]

2. Section 510.600 is amended in the table in paragraph (c)(1) by removing the entry for ''Agri–Bio Corp.'' and in the table in paragraph (c)(2) by removing the entry for ''042835''.

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

3. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: Secs. 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b, 371).

§ 558.95 [Amended]

4. Section 558.95 *Bambermycins* is amended in paragraphs (b)(1)(xi)(*b*) and (b)(1)(xii)(*b*) by removing ''042835'' and adding in its place ''000004''.

5. Section 558.550 is amended in paragraph (a)(1) by removing the number ''042835'' and adding in its place ''000004'', and by revising paragraph (a)(2) to read as follows:

§ 558.550 Salinomycin.

(a) * * *

(2) To 012799 for use of 30 and 60 grams per pound as in paragraphs (b)(1)(i), (b)(1)(iii) through (b)(1)(xvi),